Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 3
2000 1
2001 1
2002 1
2003 1
2004 1
2005 3
2006 1
2007 5
2008 5
2009 1
2010 3
2011 4
2012 4
2013 9
2014 9
2015 5
2016 4
2017 5
2018 8
2019 7
2020 12
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

84 results
Results by year
Filters applied: . Clear all
Page 1
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Luna G, et al. Among authors: fogdell hahn a. JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365. JAMA Neurol. 2020. PMID: 31589278 Free PMC article.
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Alping P, et al. Among authors: fogdell hahn a. Ann Neurol. 2020 May;87(5):688-699. doi: 10.1002/ana.25701. Epub 2020 Mar 9. Ann Neurol. 2020. PMID: 32056253 Free article.
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
Hässler S, Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S, Aktas O, Auer M, Avouac J, Birchler M, Bouhnik Y, Brocq O, Buck-Martin D, Cadiot G, Carbonnel F, Chowers Y, Comabella M, Derfuss T, De Vries N, Donnellan N, Doukani A, Guger M, Hartung HP, Kubala Havrdova E, Hemmer B, Huizinga T, Ingenhoven K, Hyldgaard-Jensen PE, Jury EC, Khalil M, Kieseier B, Laurén A, Lindberg R, Loercher A, Maggi E, Manson J, Mauri C, Mohand Oumoussa B, Montalban X, Nachury M, Nytrova P, Richez C, Ryner M, Sellebjerg F, Sievers C, Sikkema D, Soubrier M, Tourdot S, Trang C, Vultaggio A, Warnke C, Spindeldreher S, Dönnes P, Hickling TP, Hincelin Mery A, Allez M, Deisenhammer F, Fogdell-Hahn A, Mariette X, Pallardy M, Broët P; ABIRISK consortium. Hässler S, et al. Among authors: fogdell hahn a. PLoS Med. 2020 Oct 30;17(10):e1003348. doi: 10.1371/journal.pmed.1003348. eCollection 2020 Oct. PLoS Med. 2020. PMID: 33125391 Free PMC article.
Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier.
Kharlamova N, Hermanrud C, Dunn N, Ryner M, Hambardzumyan K, Vivar Pomiano N, Marits P, Gjertsson I, Saevarsdottir S, Pullerits R, Fogdell-Hahn A. Kharlamova N, et al. Among authors: fogdell hahn a. Front Immunol. 2020 Jul 21;11:1365. doi: 10.3389/fimmu.2020.01365. eCollection 2020. Front Immunol. 2020. PMID: 32793189 Free PMC article.
10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.
Tourdot S, Abdolzade-Bavil A, Bessa J, Broët P, Fogdell-Hahn A, Giorgi M, Jawa V, Kuranda K, Legrand N, Pattijn S, Pedras-Vasconcelos JA, Rudy A, Salmikangas P, Scott DW, Snoeck V, Smith N, Spindeldreher S, Kramer D. Tourdot S, et al. Among authors: fogdell hahn a. MAbs. 2020 Jan-Dec;12(1):1725369. doi: 10.1080/19420862.2020.1725369. MAbs. 2020. PMID: 32063088 Free PMC article.
Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach.
Duhazé J, Caubet M, Hässler S, Bachelet D, Allez M, Deisenhammer F, Fogdell-Hahn A, Gleizes A, Hacein-Bey-Abina S, Mariette X, Pallardy M, Broët P; ABIRISK Consortium. Duhazé J, et al. Among authors: fogdell hahn a. BMC Med Res Methodol. 2020 Mar 20;20(1):69. doi: 10.1186/s12874-020-00941-z. BMC Med Res Methodol. 2020. PMID: 32192445 Free PMC article.
Prediction of natalizumab anti-drug antibodies persistency.
Deisenhammer F, Jank M, Lauren A, Sjödin A, Ryner M, Fogdell-Hahn A, Sievers C, Lindberg R, Jensen PE, Sellebjerg F, Christodoulou L, Birchler M, Pallardy M, Auer M, Liblau R; ABIRISK consortium. Deisenhammer F, et al. Among authors: fogdell hahn a. Mult Scler. 2019 Mar;25(3):392-398. doi: 10.1177/1352458517753721. Epub 2018 Jan 16. Mult Scler. 2019. PMID: 29336205
A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort.
Duhazé J, Hässler S, Bachelet D, Gleizes A, Hacein-Bey-Abina S, Allez M, Deisenhammer F, Fogdell-Hahn A, Mariette X, Pallardy M, Broët P. Duhazé J, et al. Among authors: fogdell hahn a. Front Immunol. 2020 Apr 7;11:608. doi: 10.3389/fimmu.2020.00608. eCollection 2020. Front Immunol. 2020. PMID: 32318076 Free PMC article.
Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
Andlauer TFM, Link J, Martin D, Ryner M, Hermanrud C, Grummel V, Auer M, Hegen H, Aly L, Gasperi C, Knier B, Müller-Myhsok B, Jensen PEH, Sellebjerg F, Kockum I, Olsson T, Pallardy M, Spindeldreher S, Deisenhammer F, Fogdell-Hahn A, Hemmer B; ABIRISK consortium. Andlauer TFM, et al. Among authors: fogdell hahn a. BMC Med. 2020 Nov 4;18(1):298. doi: 10.1186/s12916-020-01769-6. BMC Med. 2020. PMID: 33143745 Free PMC article.
84 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page